Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
Ilkka RaumaTiina MustonenJuha Matti SeppäMaritta UkkonenMarianne MännikköAuli Verkkoniemi-AholaMarge KartauJukka T SaarinenLiisa LuostarinenSakari SimulaMervi RyyttyRiitta AhmasaloJussi O T SipiläIlkka PieninkeroinenTero TapiolaAnne M RemesHanna KuusistoPublished in: Journal of neurology (2021)
SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.